Bmf is a BH3-only Bcl-2 family member that is normally sequestered to myosin V motors by binding to the dynein light chain 2 (DLC2). Certain damage signals release Bmf, which then binds prosurvival Bcl-2 proteins and triggers apoptosis. Here, two novel isoforms of human Bmf, Bmf-II and Bmf-III, were identified and cloned from cDNA derived from B-chronic lymphocytic leukemia (B-CLL) cells. Bmf-II and Bmf-III were characterized as two splice variants, lacking the BH3 domain but retaining the DLC2 binding domain. Bmf (here called Bmf-I) expression in HeLa cells induced apoptosis and reduced colony formation in contrast to Bmf-II and Bmf-III, which had no effect on apoptosis and instead increased colony formation. While bmf-I mRNA was expressed in many cell types, expression was higher in B lymphoid cells and bmf-II and bmf-III were mainly detected in B-CLL and normal B cells. bmf-I mRNA was upregulated in normal and leukemic B cells, while bmf-III mRNA was downregulated only in B-CLL cells by serum deprivation. We show that Bmf is regulated by transcriptional activation and alternative splicing and conclude that the relative levels of Bmf isoforms may have a role in regulating growth and survival in B cells and leukemic B-CLL cells.
Introduction
One of the major components of the cell death machinery is the Bcl-2 family. Bcl-2 proteins possess up to four conserved Bcl-2 homology (BH) domains designated as BH1 to BH4. More than 20 Bcl-2 family members have been described, which are grouped into antiapoptotic and proapoptotic subfamilies. The proapoptotic Bcl-2 subfamily is further divided into two groups. One includes 'multi-domain' or 'Bax-like' proteins that have BH1-3 domains and the other includes 'BH3-only' proteins that share sequence homology only with the BH3 domain.
1 BH3-only family members include Bim/Bod, Bid, Bad, Bik/Nbk/Blk, Hrk, NIP3, NIX/BNIP3, Noxa, Bmf and PUMA. 1 The BH3 region within proapoptotic Bcl-2 family members is essential for heterodimerization with the prosurvival Bcl-2 relatives and for proapoptotic function. [2] [3] [4] [5] It has become clear that BH3-only proteins are critical regulators of apoptosis and play an essential role in mammalian development. 5, 6 Bmf was first cloned by Puthalakath et al 7 as a BH3-only protein that binds prosurvival Bcl-2 family members to initiate apoptosis. The apoptotic activity of Bmf is post-translationally regulated by its interaction with the myosin V actin motor complex through its binding to dynein light chain 2 (DLC2). In response to stress stimuli, such as detachment of adherent cells from their substratum (anoikis) or exposure to ultraviolet irradiation Bmf is released, together with its partner DLC2, from the myosin V motor complex. Bmf is then translocated and bind prosurvival Bcl-2 proteins, such as Mcl-1, Bcl-2, Bcl-x L and Bcl-w. 7 It is believed that Bmf together with Bim represent sentinels mounted on the main cytoskeletal structures to sense intracellular damage. 7, 8 bmf mRNA has been found in several cell lines of B-and T-lymphoid, myeloid, or fibroblast origin and in mouse embryos at all developmental stages. Bmf protein has been detected in many mouse organs, with abundant proteins in pancreas, liver, kidney and hematopoietic tissues. 7 Here, two novel isoforms of human Bmf, Bmf-II and Bmf-III, were cloned from B-CLL cDNA and their functions and expression profiles were characterized. We have found that Bmf isoforms with different apoptotic activity are subjected to regulated alternative splicing by serum deprivation apoptotic stimuli in normal and leukemic B cells.
Material and methods

Cells and reagents
Leukemic B cells were isolated from heparinized blood taken from B-CLL patients. The study was approved by the Karolinska Hospital Ethic Committee and written informed consent was obtained from all patients. Unfractionated normal B cells were isolated from tonsil tissue. Normal and leukemic B lymphocytes were obtained after carbonyl iron treatment and Lymphoprep centrifugation, and T cells were depleted by rosetting with sheep erythrocytes. Isolated cells were kept frozen in aliquots. Isolated nonrosetting, leukemic B cells contained less than 0.2% CD3 þ cells as estimated by flow cytometry. Daudi (Burkitt's lymphoma), Ramos (Burkitt's lymphoma), K562 (myelocytic leukemia), SW480 (colon carcinoma), FM3D and BE melanoma cell lines, HUT-78 (T-lymphoma), Jurkat (acute T cell leukemia), U937 (histiocytic lymphoma), HeLa (cervical carcinoma) and HEK 293T (embryonic kidney) human cell lines were purchased from American Type Culture Collection. Cell lines were cultured in RPMI 1640 medium supplemented with 10% fetal bovine serum (FBS) and antibiotics. Primers for bmf, bim and b-actin PCR amplification were synthesized by CyberGene AB (Stockholm, Sweden). Peroxidase-conjugated rabbit anti-goat Ig and peroxidase-conjugated goat anti-rabbit Ig were from Dakopatts (Copenhagen, Denmark). Rabbit polyclonal antibody to Bmf was from Alexis (Läufelfingen, Switzerland). Actin (I-19) goat polyclonal antibody was from Santa Cruz Biotechnology (Santa Cruz, CA, USA).
Cell cultures
B-CLL and normal B cells were resuspended in RPMI 1640 medium supplemented with 2 mM glutamine, 100 IU/ml penicillin, 100 mg/ml streptomycin and 0.5% bovine serum albumin (BSA fraction-V). Cells (2 Â 10 6 /ml) were incubated in 12-well plates at 371C, and 5% CO 2 in medium alone. After culture, cells were collected, at indicated times, to isolate total RNA. B-CLL cells were also cultured in 96-well plates in medium alone to assess spontaneous apoptosis. Daudi, Ramos, K562 and HUT-78 cell lines were cultured in 12-well plates (2 Â 10 6 /well) in medium nonsupplemented with FBS during 12, 24 and 48 h. SW480 and FM3D cell lines were seeded in 12-well plates (0.1 Â 10 6 /well) in medium supplemented with 10% FBS. After 48 h of culture, medium was removed and replaced with nonsupplemented medium. The plates were cultured for an additional 12, 24 and 48 h. After culture cells were collected to assess cell death by trypan blue staining and to isolate total RNA.
Apoptosis
Apoptosis induced in B-CLL and normal B cells by serum deprivation was determined by annexin-V staining. Cells were washed with PBS and incubated 10 min in 100 ml of binding buffer (10 mM HEPES/NaOH, pH 7.4, 140 mM NaCl, 5 mM CaCl 2 ) containing annexin V-Fluos solution (Roche Molecular Biochemicals, Mannheim, Germany) and 2 mg/ml propidium iodide (Sigma Chemical, St Louis, MO, USA). Cells were analyzed with a FACScan (Becton Dickinson, Mountain View, CA, USA).
Isolation and expression plasmid construction of human Bmf isoforms
Total RNAs isolated from B-CLL cells were reverse transcribed using oligo (dT) 15 primer (Promega Madison, WI, USA) and cDNAs encoding bmf were amplified by PCR with Pfu DNA polymerase (Promega) according to the manufacturer's protocol. The primers used were 5 0 -CGCGGATCCACCATGGAGC-CATCTCAGTGT-3 0 and 5 0 -CCGGAATTCTCACCTAGGGCCT-GCCCCGTT-3 0 (BamHI and EcoRI sites for cloning are underlined). bmf cDNAs were amplified by 30 cycles of 1 min at 941C, 1 min at 601C and 2 min at 721C. The amplified products were gel purified using the Geneclean II gel extraction kit (Bio 101, Vista, CA, USA), subcloned into pUC18 vector (CLON-TECH, Palo Alto, CA, USA) and the cDNA was sequenced in the ABI Prism 310 Genetic Analyzer (Applied Biosystems, Foster City, CA, USA). The sequences were matched with the reported database sequence for bmf (GenBank Accession No. AY029254). The known bmf product was here called bmf-I. The two new human bmf cDNA variants were named bmf-II and bmf-III. The three different bmf cDNAs were cloned into the pcDNA3 expression vector (Invitrogen Inc., San Diego, CA, USA). The nucleotide sequences for human bmf-II and bmf-III have been deposited with GenBank (Accession No.s: AY222040 and AY222041, respectively).
Analysis of apoptosis after transient and stable transfection
HeLa and HEK 293T cell cells were plated in 12-well tissue culture plates at a density of 0.1 Â 10 6 cells/well in DMEM medium supplemented with 10% FBS without antibiotics. After 1 day, cells were transfected using the lipofectamine procedure (Life Technologies, Gaithersburg, MD, USA) with 0.5 mg of the empty pcDNA3 vector or the same vector containing the bmf-I, bmf-II, or bmf-III cDNAs, together with 0.05 mg of the pSV-bgalactosidase vector (Promega) to allow the identification of transfected cells. Cells were incubated with plasmids in serumfree medium for 5 h at 371C, followed by the addition of FBS to a final concentration of 10%. After 48 h, cells were fixed with 0.25% formaldehyde plus glutaraldehyde and overnight stained with X-Gal 
Analysis of bmf and bim expression by reverse transcriptase-polymerase chain reaction (RT-PCR)
Total RNA was extracted with Trizol (Gibco, BRL) and quantified by spectrophotometry. A weight of 3 mg of total RNA was denatured and reverse transcribed using oligo (dT) 15 primers. PCR was performed using the following sense and antisense primers: bmf (536 bp), 5
0 -ATCTCAGTGTGTGGAG-GAGCTG-3 0 and 5
0 . PCR was performed in the exponential range of amplification with the following conditions: bmf, bim and b-actin 33, 29 and 18 cycles, respectively, of 30 s at 941C, 1 min at 601C and 2 min at 721C. The samples were then resolved on a 2% agarose gel with 1 mg/ml of ethidium bromide and photographed. Densitometric analysis was performed using Scan Analysis (Bisoft) and data were normalized using b-actin signals.
Western blot analysis
Cells were lysed at 41C in lysis buffer (5 M NaCl, 1 M Tris pH 8, 0.5%. Triton X-100, 2 mM PMSF and 10 mg/ml leupeptin) followed by high-speed centrifugation to remove cellular debris. Protein concentration was determined using the Bio-Rad protein assay (Bio-Rad Laboratories, Hercules, CA, USA). Equal amounts of protein were separated on 15% SDS-PAGE and electroblotted onto PVDF membrane (Amersham Pharmacia Biotech, Piscataway, NJ, USA). Ponceau S (Sigma) staining was used to control equal protein loading. After blocking for 1 h in 5% nonfat dry milk in PBS-Tween-20 (0.05%, v/v) the membrane was incubated with rabbit anti-Bmf polyclonal antibodies followed by horseradish peroxidase-conjugated anti-rabbit Ig. Anti-actin goat polyclonal antibodies were used to control protein loading. The proteins were visualized by using chemiluminescence according to the manufacturer's protocol (ECL, Amersham Pharmacia Biotech).
Results
Identification of Bmf-II and Bmf-III, two novel isoforms of human Bmf
When bmf-specific cDNA was amplified from B-CLL cells with RT-PCR using bmf-specific primers designed following the sequence reported by Puthalakath et al 7 several transcripts were amplified together with the known bmf transcript of 555 bp (Figure 1 ). In addition to bmf 555-bp band, two other strongly expressed bands of 492 and 390 bp were detected in B-CLL cells (Figure 1) . In an attempt to determine what these two amplification products were, the PCR products were cloned into pUC18 vector and sequenced. Analysis of nucleotide sequence revealed an open reading frame that is predicted to encode two proteins of 163 and 129 amino acids (aa) (Figure  2a, b) . The 163-aa protein was identical to the reported Bmf aa sequence, 7 except for a deletion of 21 aa, including the BH3 domain. In the 129-aa protein, the first 97 aa were identical to the reported Bmf aa sequence. The missing nucleotide stretch leads to a shift in the reading frame of the deduced protein, resulting in a different aa sequence starting at residue 98. We named these molecules Bmf-II and Bmf-III, respectively. The known Bmf product is here called Bmf-I. To determine the possible structure of the human bmf gene that support the finding of the new isoforms, we checked the Gene Bank Database (NCBI) for human homology sequences to the reported bmf mRNA. A BLAST search was performed against the latest human genome sequence (Homo sapiens chromosome 15 clone CTD-2006D8 map 15q14; Accession No. AC025429.6). Comparison of the cDNA sequences of each variant with genomic data indicates that they are produced by alternative splicing events. The bmf gene contains four exons (Figure 2b ). Based on the exon-intron structure, the bmf-II variant results from splicing out part of the exon 3 of the gene because of an 'internal' predicted 5 0 donor splice site that match with the consensus sequence YNCURAC. 9 As a result, bmf-II encodes for a protein with an aa sequence similar to bmf-I but lacking the BH3 domain. bmf-III lacks all of exon 3 and encodes for a protein with different aa sequence from residue 98, also lacking the BH3 domain. Both new isoforms retain the DLC2-binding motif located in exon 2.
Bmf-II and Bmf-III do not function as proapoptotic proteins
The different bmf cDNAs were cloned into the pcDNA3 expression vector to study the biological functions of the different isoforms. Transient transfections of pcDNA3-bmf-I, -bmf-II and -bmf-III vectors or the empty vector into HeLa and HEK 293T cells were performed to investigate their respective apoptotic ability. Stable transfections with the expression construct vectors into HeLa cells were also performed to explore the effect of the Bmf isoforms on the long-term clonal growth. Expression of Bmf-I triggered apoptosis in almost 100% of HeLa cells, and reduced formation of colonies by about 80%, which was not observed by the expression of Bmf-II and Bmf-III (Figure  3a, b) . Interestingly, Bmf-II and Bmf-III expression increased colony formation (Figure 3b ). Transiently transfected HEK 293T cells showed similar results (data not shown).
To confirm the proper expression of Bmf-I, Bmf-II and Bmf-III proteins, cell lysates obtained from transiently transfected HEK 293T cells with pcDNA3-bmf-I, -bmf-II or -bmf-III vectors or the empty pcDNA3 vector were subjected to Western blot analysis with a polyclonal anti-bmf antibody. As shown in Figure 4 , Bmf-I (M r B20 500), Bmf-II (M r B18 000) and Bmf-III (M r B14 000) proteins were detected in the correspondent transfectant but not in untransfected cells or cells transfected with the empty vector.
bmf-I, bmf-II and bmf-III mRNA expression in B-CLL, normal lymphocytes and cell lines bmf-I mRNA was expressed in many cell types, such as normal lymphocytes, leukemic cells isolated from B-CLL patients, cell lines of B-and T-lymphoid and myeloid origin as well as from colon and melanoma tumors ( Figure 5 ). However, expression of bmf-I was much higher in B-CLL and normal B cells isolated from tonsils than in all cell lines and in normal resting circulating T cells. In addition, bmf-II and bmf-III were preferentially expressed in B-CLL and normal B cells ( Figure 5 ).
Transcriptional regulation of bmf in B-CLL and normal B cells during in vitro induction of apoptosis by serum deprivation
It is known that most B-CLL cells undergo spontaneous apoptosis when cultured in vitro under suboptimal conditions. 10, 11 To investigate whether bmf expression is induced by apoptotic stimuli, RT-PCR analysis of bmf mRNA was performed in B-CLL cells before and after 6 and 12 h of culture in medium without FBS. Apoptosis was also measured after 24 and 48 h of culture under the same conditions. The expression levels of bmf-I in B-CLL cells undergoing spontaneous apoptosis were strongly upregulated in most of the studied cases, while bmf-III mRNA levels were clearly downregulated (Figure 6a ). The modulation of bmf mRNA expression during in vitro induction of apoptosis by serum deprivation occurred similarly in all B-CLL without correlation with the percentages of apoptotic cells (Figure 6a ). Percentages of spontaneous apoptosis after 6 or 12 h of cell culture were less than 10% in all the patients. Bim has been shown to be essential for induction of apoptosis in response to various apoptotic stimuli such as cytokine withdrawal in T and B lymphocytes 12 and TCR crosslinking in thymocytes. 13 In addition expression of bim mRNA, has been reported to be increased by growth factor withdrawal in hematopoietic cells. 14, 15 However, bim mRNA was downregulated in B-CLL cells undergoing spontaneous apoptosis (Figure 6a ).
Since normal B and B-CLL cells shared the pattern of high expression of the three Bmf isoforms, but normal B cells die much more rapidly in vitro (5672 % at 6 h, 8078% at 24 h), bmf expression was determined by RT-PCR after 2, 4 and 6 h of culture. After 6 h, apoptosis of normal B cells was too high to isolate RNA. A similar pattern of upregulation of bmf-I was seen in normal B cells and B-CLL cells, being evident already at 2 h (Figure 6b) . No decrease in bmf-III expression could be detected in normal B cells, and was only seen in B-CLL cells at later timepoints (Figure 6a) , showing different kinetics of modulation of mRNA expression of bmf isoforms in B-CLL, normal lymphocytes and cell lines. mRNA from various cell types was isolated and reverse-transcribed. cDNA was subjected to PCR analysis using bmf-specific primers. CLL-9, CLL-10 and CLL-11, B-CLL cells; BE and FM3D, melanoma cell lines; T cells, resting peripheral blood T cells isolated from healthy donors; B cells, isolated normal B cells from tonsils.
the two isoforms. Downmodulation of bim in response to serum deprivation in normal B cells occurred in a similar manner to B-CLL, starting within a few hours of culture (not shown).
Transcriptional regulation of bmf in tumor cell lines during serum withdrawal induced apoptosis
To investigate if the bmf expression modulation induced by serum deprivation might represent a general phenomenon, several cell lines cultured in medium without FBS were analyzed for bmf mRNA expression. Indeed, cell lines of Blymphoid (Ramos and Daudi) and myeloid (K562) origin, as well as cell lines from colon and melanoma tumors (SW480 and FM3D), all showed upregulation of bmf-I induced by the serum withdrawal stimuli, correlated with the induction of cell death (Figure 7a ). Only HUT-78 cell line did not upregulate bmf-I during the induction of apoptosis. Although bmf-III mRNA is low or not expressed in these cell lines, Daudi, K562 and FM3D cell lines showed a slight upregulation of bmf-III during induction of apoptosis by serum deprivation (Figure 7a) . Expression of bim mRNA was upregulated by serum deprivation stimuli in K562, SW480, HUT-78 and FM3D cell lines, while it was downregulated in the B-lymphoid cell lines, Daudi and Ramos (Figure 7b ).
Discussion
We have isolated and characterized two novel isoforms of human Bmf from B-CLL cells, which were named Bmf-II and Bmf-III. The variant here called Bmf-I was identical in sequence to the previously known Bmf. 7 Using the cDNA sequences encoding the three variants for comparison with human genomic database, we found that the corresponding genomic sequences for all of them were located in the chromosome 15q14, the known genomic locus for the human Bmf, 7 indicating that they are produced by alternative splicing. Bmf-II is generated as a result of the deletion of a 63-bp fragment from exon 3, which includes the BH3-enconding sequence. Therefore, except for a deletion of 21 aa, the Bmf-II aa sequence matches that of Bmf-I. Bmf-III results from the splicing out of exon 3 of the bmf gene and a change in the downstream reading frame. Thus, Bmf-III aa sequence differs from that of Bmf-I from residue 98. Both Bmf-II and Bmf-III splice variants lack the BH3 domain, while they retain the DLC2-binding motif. These results suggest that the human bmf gene have multiple splice products. In fact, we found two other weakly amplified bmf-specific transcripts in B-CLL cells (Figure 1 ), which might be additional splice variants.
The BH3 domain is known to be essential for the BH3-only protein-induced apoptosis by binding to antiapoptotic Bcl-2 like proteins. 2, 5 Our functional studies after overexpression of the three isoforms demonstrated that Bmf-II and Bmf-III isoforms, which lack the BH3 domain, did not function as proapoptotic proteins, while Bmf-I induced apoptosis, as has been reported before. 7 Our results reinforce that the proapoptotic function of Bmf, similar to other BH3-only proteins, requires the BH3 domain. 7 We observed that Bmf-II and Bmf-III expression increased the colony formation of stable transfectants, suggesting a possible positive effect on cellular survival and/or proliferation. Further functional studies on cotransfectants expressing physiological levels of these proteins are required to define the role of these new isoforms.
Here, we show that the Bmf splice variants have different cellular patterns of mRNA expression. Several cell lines from different origin showed lower expression of bmf-I as compared to B cells from B-CLL patients or isolated from tonsils. Normal resting circulating T cells also expressed much lower levels of bmf-I than B-CLL cells and normal B cells and hardly any bmf-II and bmf-III. This suggests a specific role of Bmf in B cells, which could include regulation of both apoptosis and cell growth.
The proapoptotic function of Bmf has been shown to be regulated by its sequestration to the actin cytoskeleton-based myosin V motor complex through its interaction with DLC2. 7 Certain damage signals, such as loss of cell attachment (anoikis) or exposure to actin depolymerizing drugs, unleash Bmf together with its partner DLC2 from the myosin V motor complex, allowing it to translocate, bind prosurvival Bcl-2 proteins, and inhibit their function. Phosphorylation in the DLC2-binding domain by JNK in response to stress signals has been shown to mediate the release of Bmf. 16 As Bmf-II and Bmf-III splice variants retain the DLC2-binding domain, but lack the BH3 domain, these proteins may potentially counteract the proapoptotic effect of Bmf-I by binding to the cytoskeleton and thus reducing the amounts of proapoptotic Bmf-I released in response to stress signals. Lack of transcriptional control of Bmf has been shown in thymocytes in response to several apoptotic stimuli, 7 and in granulocytes during cytokine-deprivation, although a Bmf protein accumulation was observed in the latter case. 17 For some of the BH3-only proteins, there is evidence of transcriptional control of their proapoptotic activity, which seems to be apoptotic stimuli and tissue specific. 4 This is the case for Bim, which is upregulated in apoptosis induced by withdrawal of cytokines in lymphocytes, controlled by the forkhead transcription factor FKHR-L1, 14, 15 while TCR-CD3 ligation, which induced apoptosis in thymocytes in a Bimdependent way, lead to an upregulation of Bim proteins without affectin bim transcript levels in these cells. 13 Here, we present evidence for a transcriptional regulation of Bmf in B-CLL and normal B cells as well as in several cell lines of different origin. bmf-I mRNA was upregulated in B-CLL and normal B cells undergoing apoptosis by serum deprivation stimuli, which was also generally observed in cell lines. On the other hand, bmf-III mRNA was downregulated during apoptosis in B-CLL cells. In agreement with earlier reports, we found upregulation of bim in several cell lines after serum deprivation; however, it was downregulated in B-CLL and normal B cells as well as in cell lines of B-lymphoid origin. Our results indicate a transcriptional control of Bmf, which might be cell type specific, as has been suggested for Bim. B lymphocyte numbers in the periphery is controlled by survival signals from their microenvironment, mediated by cellcell interactions and soluble factors. Lack of these signals leads to activation of apoptosis programs, which is illustrated with rapid apoptosis in vitro. B-CLL cells retain their dependence on their microenvironment, and use signals from their surrounding to promote their survival. 18 Despite their prolonged survival in vivo, the cells undergo spontaneous apoptosis when cultured in vitro under suboptimal conditions (albeit at a slower rate than untransformed B cells. 10, 11 In B-CLL, lower spontaneous and drug-induced apoptosis have been correlated with progression of the disease and unsuccessful treatment, suggesting that a more apoptosis-resistant phenotype may develop during disease progression. 11, [19] [20] [21] We found induction of bmf-I mRNA in B-CLL and normal B cells in response to serum deprivation when cultured in vitro, suggesting that Bmf plays a role in the initiation of apoptosis in B cells when the proper survival keys are not present. Interestingly, in B-CLL the proapoptotic Bmf isoform (Bmf-I) was upregulated, while the nonapoptotic variant Bmf-III was downregulated after 12 h of culture. This downmodulation could not be detected in normal B cells as it occurred with delayed kinetics compared to the induction of bmf-I and after the majority of normal B cells had already undergone apoptosis. Modulation of bmf and bim mRNA expression in cell lines during apoptosis induction by serum deprivation. mRNA was isolated from several cell lines before and at the indicated time-points after culture in medium without FBS. mRNA was analyzed for bmf (a) and bim (b) expression by RT-PCR. The mRNA levels were determined by densitometric analysis and normalized according to b-actin mRNA expression. The percentage of cell death was determined in the culture by trypan blue staining. Results shown are representative of two independent experiments.
Neither could it be seen in any of the cell lines were cell death occurred at a slower pace. Given a possible prosurvival role of the Bmf-III isoform, indicated by the increase in colony formation capacity in stably transfected cells, it is possible that in B-CLL cells upregulation of Bmf-I is not enough to induce apoptosis, but in addition Bmf-III downregulation is required for apoptosis to occur.
BH3-only proteins have been recognized as essential initiators of apoptosis and it is likely that individual family members are critical for the initiation of distinct developmentally programmed cell deaths. 4 We have found here that differences in apoptosis sensitivity of B-CLL cells are not explained by different Bmf expression or modulation during induction of apoptosis. Neither could we see any difference in Bmf expression and modulation between cells from patients in stable or progressive disease. Our results suggest that Bmf might be a critical initiator for B-CLL apoptosis, at least in the absence of survival factors, but the cell survival decision may be under additional control of other Bcl-2 family proteins, or apoptosisregulating proteins. A similar mechanism has been suggested for Bim in hematopoietic cells. 22 In B-CLL, increased Bcl-2/Bax ratios have been correlated with progression, refractory disease and shorter survival. 11, 23 Mcl-1 expression has also been found as a predictor of B-CLL resistance to chemotherapy. 24 We have found higher mRNA expression of the antiapoptotic Bcl-2-like proteins, Bfl-1, Bcl-2 and Mcl-1 in apoptosis-resistance B-CLL cells as compared with sensitive B-CLL. Moreover, bfl-1 mRNA was downregulated in B-CLL cells undergoing apoptosis induced by serum deprivation, which was correlated with the degree of apoptosis sensitivity of B-CLL cells (unpublished observations). It has been demonstrated that Bmf interacts with Mcl-1, Bcl-2, Bcl-x L and Bcl-w. 7 However, Bmf interactions with Bfl-1 as well as their mechanism of action require further investigation.
Our results indicate that survival signals in vivo may promote survival in B-CLL and normal B cells by some yet undefined regulatory mechanism of bmf transcription. Based on our findings that some isoforms of Bmf have proapoptotic activity while others do not, that the splice variants show different patterns of expression and that their mRNA are differently regulated during induction of apoptosis, we suggest that transcriptional activation and alternative splicing events serve as key regulatory steps in the expression of Bmf. These mechanisms together with the reported post-translational control of Bmf relocalization 7 may fine-tune the proapoptotic activity of Bmf, resulting in either triggering or inhibition of the cellular apoptotic response.
